Generic drug design-defect claims preempted

In a victory to generic pharmaceutical companies, the U.S. Supreme Court ruled today that state design-defect laws that impose a duty on generic drug makers to either change their labeling in violation of federal law or pull the drug from the market are preempted.

Leave a Reply

Your email address will not be published. Required fields are marked *